Here are the 424B prospectus supplements from Codexis, Inc. (CDXS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CDXS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CDXS filings page.
Codexis, Inc. is conducting a primary offering of 16,666,667 shares of common stock at $1.50 per share, for gross proceeds of $25,000,000.50. Underwriters receive $0.09 per share in underwriting discounts and commissions, with Codexis expecting net proceeds of approximately $23.1 million after fees and expenses.
The company has granted underwriters a 30-day option to purchase up to 2,500,000 additional shares; if fully exercised, gross proceeds would be $28,750,000.50 and net proceeds about $26.6 million. Net proceeds are intended for working capital and general corporate purposes, including research, development and business activities, and potentially acquisitions or investments.
Codexis reports preliminary, unaudited total revenue of at least $14.8 million for the quarter ended June 30, 2026 and cash, cash equivalents and short-term investments of approximately $54.9 million as of that date. As of March 31, 2026, net tangible book value was $40.8 million, or $0.45 per share; after this offering it would have been about $63.8 million, or $0.59 per share, implying immediate dilution of $0.91 per share to new investors.
Codexis, Inc. is conducting a primary offering of common stock under its existing shelf registration, with Piper Sandler, Cantor Fitzgerald and Craig-Hallum as underwriters and a 30‑day option for the underwriters to purchase additional shares. The company’s common stock trades on Nasdaq under “CDXS,” and the last reported sale price was $2.06 per share on July 22, 2026. This sale will provide cash directly to Codexis.
Codexis reports preliminary, unaudited total revenue of at least $14.8 million for the quarter ended June 30, 2026 and expects $54.9 million in cash, cash equivalents and short‑term investments as of that date. As of March 31, 2026, it had 90,894,742 shares outstanding and a net tangible book value of $40.8 million, or $0.45 per share, meaning new investors will experience immediate dilution relative to the offering price.
The company uses its proprietary CodeEvolver directed evolution platform to engineer enzymes for small‑molecule pharmaceutical manufacturing and its ECO Synthesis platform for RNA interference therapeutics manufacturing. Net proceeds are intended for working capital and general corporate purposes, including research, development and business activities, with broad management discretion. Codexis does not expect to pay cash dividends and highlights risks including dilution from this and future equity offerings, potential stock price pressure from additional share sales, and uncertainty about maintaining an active trading market.